PMID- 21518139
OWN - NLM
STAT- MEDLINE
DCOM- 20110913
LR  - 20110719
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 102
IP  - 8
DP  - 2011 Aug
TI  - Autologous CTL response against cancer stem-like cells/cancer-initiating cells of 
      bone malignant fibrous histiocytoma.
PG  - 1443-7
LID - 10.1111/j.1349-7006.2011.01962.x [doi]
AB  - Malignant fibrous histiocytoma (MFH) of the bone is an aggressive tumor with high 
      rates of local recurrence and metastasis. The development of novel therapeutic 
      approaches is critical to improve the prognosis of patients with MFH. We reported 
      previously that the side population (SP) cells of the MFH2003 bone MFH cell line 
      have the characteristics of cancer stem-like cells (CSC)/cancer-initiating cells. 
      In the present study, to establish immunotherapy targeting CSC, we analyzed cell 
      surface immune molecules on SP cells of the MHF2003 cell line, as well as 
      autologous CTL responses against these SP cells in the tumor microenvironment and 
      peripheral circulating lymphocytes, using autologous tumor-infiltrating 
      lymphocytes and autologous CTL clones derived from peripheral blood, 
      respectively. We found that the SP cells expressed human leukocyte antigen (HLA) 
      Class I molecules on the cell surface. The autologous tumor-infiltrating 
      lymphocyte line TIL2003 recognized both the SP and main population cells of the 
      MFH2003 cell line. Next, we induced the CTL clone Tc4C-6 by mixed lymphocyte 
      tumor cell culture using autologous peripheral blood mononuclear cells and 
      freshly isolated SP cells, followed by a limiting dilution procedure. The Tc4C-6 
      clone showed specific cytotoxicity against the SP cells. Moreover, the 
      cytotoxicity against SP cells was blocked by the anti-HLA Class I antibody W6/32. 
      In conclusion, the findings of the present study support the idea that CSC of 
      bone MFH are recognized by autologous CTL in the tumor microenvironment and 
      peripheral circulating lymphocytes. Thus, CTL-based immunotherapy could target 
      CSC of bone sarcoma to help prevent tumor recurrence.
CI  - (c) 2011 Japanese Cancer Association.
FAU - Kano, Masanobu
AU  - Kano M
AD  - Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Tsukahara, Tomohide
AU  - Tsukahara T
FAU - Emori, Makoto
AU  - Emori M
FAU - Murase, Masaki
AU  - Murase M
FAU - Torigoe, Toshihiko
AU  - Torigoe T
FAU - Kawaguchi, Satoshi
AU  - Kawaguchi S
FAU - Wada, Takuro
AU  - Wada T
FAU - Yamashita, Toshihiko
AU  - Yamashita T
FAU - Sato, Noriyuki
AU  - Sato N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110531
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
SB  - IM
MH  - Bone Neoplasms/immunology/*therapy
MH  - Cell Line, Tumor
MH  - Cytotoxicity, Immunologic
MH  - Histiocytoma, Malignant Fibrous/immunology/*therapy
MH  - Humans
MH  - Immunotherapy
MH  - Lymphocytes, Tumor-Infiltrating/immunology
MH  - Neoplastic Stem Cells/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 2011/04/27 06:00
MHDA- 2011/09/14 06:00
CRDT- 2011/04/27 06:00
PHST- 2011/04/27 06:00 [entrez]
PHST- 2011/04/27 06:00 [pubmed]
PHST- 2011/09/14 06:00 [medline]
AID - 10.1111/j.1349-7006.2011.01962.x [doi]
PST - ppublish
SO  - Cancer Sci. 2011 Aug;102(8):1443-7. doi: 10.1111/j.1349-7006.2011.01962.x. Epub 
      2011 May 31.